Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity.

They found no significant differences in pain scores on the McGill Pain Questionnaire between those injected with BoNT and those injected with placebo ( P >0.05), although they did find improvements in hygiene on the DAS ( P <0.05) with a similar trend toward significance for improvement on the DAS dressing scale ( P =0.061). 41 There are few trials comparing BoNT serotypes.

also in 304 other papers

Dressing, hygiene, cosmesis, and pain demonstrated a nonsignificant trend to a greater reduction in the primary therapeutic target 6 weeks after injection in the onabotulinumtoxinA group. 36 IncobotulinumtoxinA Two class I trials have demonstrated reduction in tone with incobotulinumtoxinA.

also in 5,406 other papers